InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2021-07-02 00:00:00 ET · period of report 2021-06-30 · accession 0001654954-21-007593 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-07-02 2021-06-30 MNPR Robinson Chandler CEO, Dir F - Tax $5.89 -2,310 24.0K -9% -$13.6K
D 2021-07-02 2021-06-30 MNPR Robinson Chandler CEO, Dir M - OptEx — +7,883 26.3K +43% —
D 2021-07-02 2021-06-30 MNPR Robinson Chandler CEO, Dir M - OptEx $0.00 -7,883 55.2K -13% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-06-30 F D 2,310 $5.89 23,972.80 D — —
2 Common Common Stock 2021-06-30 M A 7,883 — 26,282.80 D — — (F1) Represents shares acquired on vesting and settlement of restricted stock units.
3 Derivative Restricted Stock Units 2021-06-30 M D 7,883 $0.00 55,177 D — · — to — 7,883 Common Stock (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.